Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 1c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18